Improve your management and care of patients with liver failure with this long-running study day.
Improve your management and care of patients with liver failure with this long-running study day. In depth talks will be given by dieticians, sports scientists and geneticists as well as clinicians, on topics such as nutrition in the pre-transplant NAFLD patient, acute-on-chronic liver failure and unrecognised problems in ICU patients.
Topics covered will allow you to:
Programme details below from 9.15am:
Title of Talk |
Faculty |
General introduction to the day |
Tony Whitehouse, Consultant Critical Care, Queen Elizabeth Hospital, Birmingham |
Pre-habilitation and nutrition in the pre-transplant NAFLD patient |
Matt Armstrong, Consultant Hepatologist, QEHB |
Q&A |
|
The acute management of the severely ill adult with a metabolic condition |
Tarekegn Hiwot/Charlotte Dawson, Consultant Metabolic Medicine, QEHB |
Q&A |
|
Coffee break |
|
Malabsorption diarrhoea in liver patients on ICU – an unrecognised problem? |
Ruth S. Chinuck, Clinical Lead – Dietetics, QEHB Dr Jill Johnson - Lecturer and Principal Investigator (Biosciences) at Aston University |
Q&A |
|
Nutrition in acute liver failure |
Will Bernal, Consultant Intensivist, King’s College Hospital |
Q&A |
|
Lunch break |
|
Acute-on-chronic liver failure |
Abhishek Chauhan, University Hospitals Birmingham NHS Foundation Trust |
Q&A |
|
Albumin should no longer be used in the ICU |
Pro – Alastair O’Brien, Consultant Hepatologist, University College London Con – Mansoor Bangash, Consultant Critical Care, Queen Elizabeth Hospital, Birmingham |
Q&A |
|
Closing Remarks |
Tony Whitehouse |
Close |
|
Consultant in metabolic medicine, Queen Elizabeth Hospital Birmingham
William Bernal is Consultant and Professor of Liver Critical Care Medicine in the Liver Intensive Therapy Unit at the Institute of Liver Studies at Kings College Hospital in London UK. He is part of a small consultant team running a 19 bedded specialist critical care unit devoted to the care of patients with severe liver and pancreatic disease, and which serves one of the largest liver transplantation programs in Europe.
He trained in General Medicine at the Royal London and St Bartholomew’s Hospital in London and in Hepatology and Intensive Care Medicine at Guys and St Thomas and Kings College Hospitals. His research interests include the pathogenesis and management of acute and acute-on-chronic liver failure, and the utilization of liver transplantation in emergency settings.
Abhishek is a Consultant Hepatologist in the University Hospital Birmingham and Senior Lecturer in the Centre for Liver and Gastrointestinal research, University of Birmingham. He trained in General Medicine at various hospital in the West Midlands and in Transplant Hepatology on the Birmingham Liver transplant Unit. His research interests centre around innate immunity and how this influences acute liver inflammation in the context of acute and acute-on-chronic liver failure.
Ruth is the Clinical Lead for Dietetics at the Queen Elizabeth Hospital, Birmingham. Co-secretary, British Dietetic Association’s (BDA) Critical care specialist group for the UK. She has worked within Dietetics for over 25 years in a variety of clinical areas, including Adult Cystic Fibrosis, transplantation; now specialising in intensive care.
Goals: To create a Consultant ITU Dietetic post.
Aspirations: To lead multi-therapy academic research in indirect calorimetry and transplantation on ICU.
Achievements: Silver award for education and training in multi-therapy clinical supervision at UHB, British Dietetic Association Winner for the COVID-19 response as part of the BDA critical care specialist group, Role of Honour from the British Dietetic Association for Supplementary Prescribing and Specialist Advisor for the Care Quality Commission.
Consultant in metabolic medicine, Queen Elizabeth Hospital Birmingham,
Charlotte did an undergraduate degree and PhD in Biochemistry before embarking on medical training. She completed specialist training in Metabolic Medicine in Bristol and was appointed as a consultant in Metabolic Medicine at University Hospitals Birmingham in 2012. The department of Inherited Metabolic Disorders in Birmingham is one of five nationally recognised centres in England for the treatment of patients with inherited metabolic disorders and includes outreach services in Bristol, Taunton and Sheffield. Charlotte and colleagues run over 30 clinical trials and registries, including trials of novel gene and mRNA-based treatments for inherited metabolic disorders.
Alastair is Professor of Hepatology at UCL and Consultant Hepatologist at UCLH and The Royal Free Hospitals. His research combines laboratory work with large scale clinical trials and aims to improve outcomes from infection in patients with decompensated cirrhosis. His group discovered that elevated circulating Prostaglandin E2 was a key underlying mediator for macrophage dysfunction in cirrhosis (O’Brien et al, Nature Medicine 2014). Alastair was also the chief investigator for the ATTIRE trial (Albumin to prevent infection in chronic liver failure) published in NEJM (China et al, 2021) and is currently leading the ASEPTIC trial (Primary Antibiotic Prophylaxis using Cotrimoxazole to Prevent Spontaneous Bacterial Peritonitis in Cirrhosis) throughout the UK.
Professor of Intensive Care Medicine ,
Tony is a critical care consultant based at the Queen Elizabeth Hospital in Birmingham.
He qualified from University College London in 1992 and after initial training in the North London Region, completed his MD with Prof Mervyn Singer. He dual-accredited in anaesthesia and intensive care in 2004 and was appointed to Birmingham shortly afterwards.
Since then he has built clinical research in the largest Intensive Care in the UK. He is principal investigator for a number of studies on the NIHR portfolio. He is regional co-lead for Critical Care at the Midland CRN and Chief Investigator for the NIHR-funded STRESS-L study. He is also investigating the use of large datasets for outcomes in critical care and a study of the microbiome in critically ill patients. He collaborates with the Microbiology Department in the University of Birmingham (UoB) studying Bacteriophage, MDR E coli and MicroRNA dynamics in the gut microbiome and also the Department of Clinical Bioinformatics (also UoB) investigating the management of patients undergoing Oesophagectomy and having treatment with Albumin.
He is working with members of the Turing Institute to analyse treatments used during the COVID-19 pandemic.